Dual-Action 5-HT1A and SSRI Derivatives for Neurological Disorders

Solution Overview

Problem

Current treatments for neurological disorders such as depression, anxiety, and schizophrenia lack effective dual-action compounds that simultaneously target 5-HT 1A receptors and serotonin reuptake inhibitors, leading to suboptimal therapeutic outcomes and side effects.

Innovation Solution

Development of a novel compound, specifically N-[(4-hydroxypiperidin-4-yl)methyl]pyridin-2(1H)-one derivatives with dual activities as 5-HT 1A receptor ligands and selective serotonin reuptake inhibitors, which can be used to treat various neurological and psychiatric disorders.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If separate medications for 5-HT1A receptor and serotonin reuptake are used, then therapeutic coverage is comprehensive, but treatment complexity and side effects increase

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent combines two separate pharmacological functions (5-HT1A receptor agonism and serotonin reuptake inhibition) into a single dual-action compound. This merging approach allows the compound to simultaneously target both mechanisms, providing comprehensive therapeutic coverage for depression and anxiety while reducing treatment complexity and potential drug-drug interactions compared to using separate medications

Inventive Principle:
Principle #5Merging (Combining)

Solution Approach 2:

The compound exhibits multi-functionality by acting as both a 5-HT1A receptor agonist and a serotonin reuptake inhibitor. This universal action across multiple targets within the serotonin system enables the single compound to address multiple aspects of mood and anxiety disorders, replacing the need for multiple specialized medications

Inventive Principle:
Principle #6Universality (Multi-functionality)

2Productivity

If dual-action compounds are developed, then therapeutic efficiency is enhanced, but drug development complexity increases

Engineering Contradiction:
Core Design Contradiction:
ProductivityVSDevice complexity

Solution Approach 1:

The drug development process merged two distinct pharmacological activities into a single molecular entity. By combining the 5-HT1A agonist pharmacophore with the serotonin reuptake inhibitor structural features, the researchers created a dual-action compound that delivers enhanced therapeutic efficiency through simultaneous multi-target engagement

Inventive Principle:
Principle #5Merging (Combining)

Solution Approach 2:

The dual-action compound represents a composite molecular structure integrating features of both 5-HT1A agonists and SSRIs. This composite design allows the molecule to interact with multiple biological targets, achieving synergistic therapeutic effects that exceed the sum of individual single-action compounds

Inventive Principle:
Principle #40Composite materials

3Ease of operation

If conventional single-action medications are used, then drug simplicity is maintained, but onset time and therapeutic effect are limited

Engineering Contradiction:
Core Design Contradiction:
Ease of operationVSLoss of time

Solution Approach 1:

The patent maintains drug simplicity by using a single oral medication rather than multiple drugs, while simultaneously accelerating onset time through dualmechanism action. The combined 5-HT1A agonism and serotonin reuptake inhibition provide rapid initial anxiolytic and antidepressant effects, reducing the waiting period for therapeutic response compared to conventional single-action medications

Inventive Principle:
Principle #5Merging (Combining)

Data Source

PatentEP2570410B11-[(4-hydroxypridin-4-YL) methyl]pyridine-2(1H)-one derivatives, preparation methods and uses thereof
Publication Date: 2018.11.21
  • EP2570410B1 patent drawingFigure 1~2
  • EP2570410B1 patent drawingFigure 3
  • EP2570410B1 patent drawing

AI summary

Provided are N-[(4-hydroxypiperidin-4-yl)methyl]pyridin-2(1H)-one derivatives represented by formula I, stereoisomers, pharmaceutically acceptable salts or solvates thereof. The above compounds have the dual activities of 5-hydroxytryptamine 1A receptor ligand and selective serotonin reuptake inhibitor. The preparation methods of the above compounds, the uses of these compounds for the prevention or treatment of nervous system diseases related to 5-hydroxytryptamine system dysfunction and the pharmaceutical compositions containing these compounds are also provided.